Roivant Sciences Ltd. — Form 10-Q Summary
Period clarification: The filing is for the three months ended June 30, 2023 (Roivant’s fiscal first quarter of fiscal 2024), compared with the three months ended June 30, 2022. This differs from the request metadata’s “2022 Q1.” Amounts below are in U.S. dollars; financial-statement amounts are generally in millions unless stated otherwise.
Business context and reporting period
Roivant is a commercial-stage biopharmaceutical company that develops and commercializes medicines through subsidiaries known as “Vants.” VTAMA (tapinarof) is its first FDA-approved product, approved for adult plaque psoriasis in May 2022. Its pipeline includes programs in inflammation and immunology, including VTAMA for atopic dermatitis, RVT-3101, brepocitinib, batoclimab and IMVT-1402. The unaudited interim statements are prepared under U.S. GAAP.
Financial performance and position
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Revenue, net | $21.6 | $4.3 |
| Product revenue, net | $16.7 | $0.1 |
| Operating expenses | $298.0 | $286.6 |
| Loss from operations | $(276.4) | $(282.3) |
| Net loss | $(327.8) | $(353.8) |
| Net loss attributable to Roivant | $(291.8) | $(331.8) |
| Basic and diluted loss per share | $(0.38) | $(0.48) |
| Net cash used in operating activities | $(249.9) | $(252.1) |
- Revenue and margins: Product revenue rose to $16.7 million following VTAMA’s launch. Cost of revenues was $4.2 million, including $0.7 million of VTAMA-related costs and $2.4 million of amortization of capitalized milestones. The filing does not provide a clear consolidated gross-margin measure.
- Cash and liquidity: At June 30, 2023, cash and cash equivalents were $1.434 billion; cash, cash equivalents and restricted cash totaled $1.450 billion. Current assets were $1.561 billion and current liabilities $245.0 million. Management said cash and cash equivalents were expected to fund committed operating expenses and capital expenditure requirements for at least 12 months from issuance of the statements, and separately estimated cash runway into the second half of calendar 2025.
- Debt: Balance-sheet current and long-term debt totaled approximately $429.5 million, including the NovaQuest facility, Dermavant’s credit facility and the tapinarof revenue-interest financing. NovaQuest debt is measured at fair value and its valuation may fluctuate.
- Cash flows: Investing activities provided $0.1 million; financing activities provided $7.5 million. Cash, cash equivalents and restricted cash fell $242.5 million during the quarter.
Material changes versus the prior comparable period
- Revenue increased $17.3 million, primarily because VTAMA product sales grew from a minimal launch-period base. Management reported a 26% gross-to-net yield for VTAMA in the quarter.
- Operating expenses rose $11.4 million. R&D fell $10.7 million to $125.1 million, reflecting discontinued or reprioritized programs and lower share-based compensation, partly offset by increased spending on the anti-FcRn franchise, RVT-3101 and namilumab.
- SG&A increased $7.1 million to $156.2 million; higher Dermavant commercialization costs more than offset lower share-based compensation.
- Acquired in-process R&D expense was $12.5 million, related to batoclimab development and regulatory milestones; there was no comparable charge in the prior-year quarter.
- Operating loss narrowed by $5.9 million and Roivant-attributable net loss narrowed by $40.0 million. The quarter still included $54.5 million of losses from changes in fair value of debt and liability instruments, partly offset by higher interest income of $16.7 million.
- Operating cash use was broadly similar year over year. Financing cash inflow was much lower than in the prior-year quarter, which included $160 million of RIPSA funding following VTAMA’s FDA approval.
Outlook, developments, risks and unusual items
- Outlook: Management expects R&D expenses to rise as programs advance and new assets are pursued, and SG&A to increase as commercialization infrastructure expands. It expects to fund operations through existing cash and potentially future equity, debt, subsidiary sales and collaboration or licensing proceeds. It cautions that financing may not be available on acceptable terms and that spending or development plans may need to be reduced if capital is insufficient.
- Pipeline and commercial updates: The filing reports positive Phase 3 ADORING 1 results for VTAMA in atopic dermatitis, with no new safety or tolerability signals reported in that study; an sNDA filing was expected in the first quarter of 2024. Telavant reported positive chronic-period TUSCANY-2 results for RVT-3101 in ulcerative colitis. The filing also lists expected clinical catalysts through 2025; timing is subject to change and, where applicable, regulatory feedback.
- Commercialization: As of August 2023, Roivant reported nearly 200,000 VTAMA prescriptions and coverage across 129 million U.S. commercial lives and 87 million government lives, based on cited third-party data. These are management-reported indicators, not guarantees of future sales or profitability.
- Subsequent events: In July 2023, SK invested $6 million in VantAI preferred shares. In August 2023, SK Biopharmaceuticals purchased Roivant’s Proteovant shares for $47.5 million. Roivant also announced redemption of outstanding warrants for $0.10 each after September 1, 2023, with holders able to make a cashless exercise before the deadline under specified terms.
- Commitments and contingencies: Minimum purchase commitments included approximately $44.7 million for VTAMA supply and $26.5 million for batoclimab manufacturing; remaining Palantir subscription payments were $19.1 million. The Immunovant securities lawsuit remained pending; the company had not accrued a liability because it could not reasonably estimate possible losses or determine whether an unfavorable outcome was probable. Genevant and Arbutus also faced patent-related litigation; Acuitas refiled its declaratory judgment action in New Jersey after dismissing its New York action.
- Key risks: Continued operating losses and cash burn; dependence on VTAMA commercialization and payer access; clinical, regulatory and manufacturing uncertainty; need for additional capital and potential dilution; third-party supply reliance; intellectual-property disputes; and valuation volatility in Level 3 investments and liabilities. Roivant reported disclosure controls and procedures were effective as of June 30, 2023, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the period being analyzed: the filing covers the quarter ended June 30, 2023, not 2022 Q1.
- Track VTAMA prescription growth, net sales, gross-to-net deductions, payer coverage, supply costs and progress toward the expected atopic-dermatitis filing.
- Compare quarterly operating cash burn with management’s stated runway estimate and assess the assumptions underlying the second-half-2025 runway outlook.
- Review debt repayment and payment terms, including NovaQuest’s contingent payments and the revenue-interest financing tied to VTAMA sales.
- Monitor upcoming clinical readouts and regulatory milestones, recognizing that timing and preliminary results may change.
- Assess outcomes and potential financial effects of the disclosed securities and patent litigation, and the final effects of the warrant redemption and subsequent transactions.